Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Strategies

Set Alert for Pricing Strategies

US Government Proposals Would Obligate Health Plans To Place Generics On Correct Tiers

The HHS and CMS have proposed that health plans in the US be required to place generic and brand drugs on the correct tiers for their drug category.

Generic Drugs Legislation

Adalimumab Expectations Revised In The Wake Of Amgen Launch

The launch of Amgen’s Amjevita, the first US biosimilar rival to Humira, has been accompanied by multiple fresh forecasts of how competition could play out this year, with a host of further biosimilar launches on the horizon.

Biosimilars United States

Amgen Talks Dual Pricing Strategy For Amjevita

In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.

Biosimilars Pricing Strategies

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount

Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.

Biosimilars Launches

Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component

Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Generic Drugs Launches

Scale Of Off-Patent Savings Ramps Up As Impact Of Biologic LOEs Increases

IQVIA’s latest Global Use of Medicines report demonstrates the impact generics and biosimilars are set to have on global pharmaceutical spending, with losses of exclusivity expected to dampen spending growth over the next five years.

Generic Drugs Biosimilars

German Generic Reform To Relax Pediatric Pricing

Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.

Germany Generic Drugs

Biosimilars Forum Urges Equal Access For US Humira Rivals

With the US on the cusp of biosimilar competition to Humira, Julie Reed – executive director of the country’s Biosimilars Forum – has urged PBMs to bolster access by making all adalimumab biosimilars available as they launch throughout 2023.

Biosimilars United States

International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation

Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.

Business Strategies Market Intelligence
See All
UsernamePublicRestriction

Register